Some suggested that low MME expression levels are associated with poor prognosis in ovarian and prostate cancers, and that MME depletion leads to Akt activation and hence contributes to cancer clinical progression (Ffrench et al., 2017; Osman et al., 2006). This evidence concerns the gene AKT1 and prostate carcinoma.